Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
18F-FDG
The First People's Hospital of Lianyungang
Multiple Myeloma and Malignant Plasma Cell Neoplasms
1 trial -
1mg KHK7580
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy Volunteer
1 trial -
68Ga-AAZTA-NI-093
The First People's Hospital of Lianyungang
Prostate Cancer (Adenocarcinoma)
1 trial -
68Ga-BNU-PSMA
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
The First People's Hospital of Lianyungang
177Lu-DOTA-FAPI
1 trial -
68Ga-DOTA/NOTA-FAPI-04
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-FAPI-04
The First People's Hospital of Lianyungang
Liver Fibrosis
1 trial -
68Ga-FAPI-Biotin
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-JH04
The First People's Hospital of Lianyungang
Malignant Neoplasm
1 trial -
68Ga-JH12
The First People's Hospital of Lianyungang
Malignant Neoplasm
1 trial -
68Ga-MGS5
The First People's Hospital of Lianyungang
Medullary Thyroid Carcinoma
1 trial -
68Ga-NODAGA-SNA006
The First People's Hospital of Lianyungang
Solid Tumor
1 trial -
68Ga-NOTA-MAL-Cys39-exendin-4
The First People's Hospital of Lianyungang
Insulinoma
1 trial -
68Ga-PSMA-11
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
68Ga-Pentixafor
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
99mTc-QULIC-5-P1
The First People's Hospital of Lianyungang
Prostate Cancer Stage
1 trial -
A-CAR028
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
AFN50 injection
The First People's Hospital of Lianyungang
Autoimmune Diseases
1 trial -
ASC30
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Weight Management
1 trial -
ASC47
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Weight Management
1 trial -
ATHENA CAR-T
The First People's Hospital of Lianyungang
Lupus Erythematosus, Systemic
1 trial -
AZD5363+Olaparib+Durvalumab
Hospital Authority, Hong Kong
Solid Tumor, Adult
1 trial -
Abatacept
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Dermatomyositis
1 trial -
Adebrelimab
The First People's Hospital of Lianyungang
Biliary Tract Malignancies
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources